This panel aids in prognostication and therapeutic decisions for Lung carcinoma where mutation has been demonstrated in MET, BRAF, EGFR, ERBB2 and KRAS and copy number variations in ALK1, ROS1 and MET. It also enables the screening of clinically actionable targets for personalized targeted medicine in Lung adenocarcinoma.